A combination of enzalutamide and leuprolide, already approved for metastatic prostate cancer, now demonstrates a significant survival benefit when used earlier in treatment. For men whose prostate cancer recurred after surgery or radiation, this drug combo reduced the risk of death by more than 40% compared to standard hormone therapy alone.
Addressing Recurrent Prostate Cancer
Prostate cancer often returns in about one-third of patients after initial curative surgery or radiation. This recurrence is frequently detected through a rising prostate-specific antigen (PSA) level, with a doubling time of nine months or less indicating high risk for developing metastases and death. Until now, treatment options for these patients have been limited.
EMBARK Trial Validates Earlier Use of Drug Combination
The phase 3 EMBARK trial enrolled over 1,000 high-risk patients across 17 countries, randomly assigning them to leuprolide alone, enzalutamide alone, or the combination. After eight years, the combination therapy arm had an overall survival rate of 78.9%, compared to 69.5% in the leuprolide-only group, translating into a 40% reduction in death risk. Enzalutamide alone did not significantly improve survival.
Shifting Treatment Paradigm Toward Earlier Intervention
This study supports a growing trend in prostate cancer management to treat aggressively earlier, rather than waiting for confirmed metastasis on imaging such as CT scans. Early intervention with the drug combo delays progression and now conclusively improves survival, offering hope for better long-term outcomes.
Balancing Benefits with Side Effects and Risks of Overtreatment
Despite these benefits, the combination therapy is associated with side effects including hot flashes, fatigue, gynecomastia, nipple pain, bone fractures, and falls. Physicians must balance these risks against the survival gains, especially given the potential for overtreatment in patients who may not progress to metastasis.
Limitations: Imaging Technology and Patient Selection
The EMBARK trial did not use PSMA PET scans, which can more accurately detect metastatic cancer than traditional imaging. This raises questions whether some participants had undetected metastases, possibly influencing the observed benefit. Understanding which patients gain the most survival advantage from early combination therapy remains an area for further research.
Expert Perspectives on Prostate Cancer Management
Dr. Stephen Freedland of Cedars-Sinai Medical Center emphasized the advances in management, stating earlier treatment is better for appropriate patients, while cautioning that not all men will die from their prostate cancer if treated early. Oncologist Dr. Edmund Folefac highlighted how improved therapies allow intervention before disease progression becomes visible on scans.
Dr. Kristen R. Scarpato of Vanderbilt University stressed vigilance regarding side effects and avoiding overtreatment. Clinicians should carefully evaluate each patient’s risk to optimize treatment balance.
Related topics
